Photoacoustic Imaging: Technology, Market and Trends

From research labs to clinical products

Clémentine Bouyé and Marc Faucheux

A new report by Tematys with Laser & Medical Devices Consulting, both France, studies photoacoustic imaging technologies and systems from research labs to clinical products and provides an understanding of the market, current and future trends.

Since the first images obtained in 2000, photoacoustic imaging (PAI) has raised more and more interest for biomedical and medical applications. First applications were found in research and development. A lot of proofs of concept for in vitro and in vivo diagnostics and monitoring have been established.

Currently, PAI is spreading to biomedical and medical markets. The three main segments are:

- Pre-clinical (drug efficiency monitoring on small animal),
- Analytics (microscopy, flow cytometry for in vitro diagnosis),
- Clinical (early stage diagnosis).

In 2016, the total PAI biomedical and medical market was worth $35 M, due to the pre-clinical and analytics segments only. It is forecasted to reach around $240 M in 2022. A sharp increase is expected starting from 2018, due to the release of clinical products that are to be approved in 2017 like the “Imagio” system from Seno Medical Instruments, US (already CE marked).

Within four to five years, the clinical market is expected to become the largest segment of the PAI biomedical and medical market, ahead of pre-clinical applications. The main applications that will benefit from PAI clinical products are cancer diagnostic, cardiovascular diseases, dermatology, brain imaging, therapy monitoring and drug developments.

In healthcare and life science, there is a huge demand for high resolution imaging at high penetration depth, in real time and at an affordable price. With an appropriate combination of optical and acoustical means, added to data processing and specific algorithms, photoacoustic imaging offers several...
advantages over other biomedical and medical imaging modalities:

- **Safe and non-invasive**: it is therefore adapted for repeated use on in vivo tissues, and is suited for treatment monitoring contrary to X-rays.
- **Label-free**: avoids the issue of approved labels in in vivo imaging.
- **Speckle free**: contrary to OCT and ultrasonography. It provides higher quality images.
- **Scalable**: PAI allows to image biological objects from organelles and cells to tissues or organs, while keeping the same high depth vs. resolution ratio.
- **High penetration depth**: up to several centimeters, allowing to image in 3D whole organs or body parts (like breast)
- **Provides various types of information**: anatomical, functional, molecular and kinetic information.

In view of all those assets, one can wonder whether PAI could replace other techniques like X-rays for various major imagery applications like breast cancer detection and screening.

The report provides an overview of optical and acoustic technologies forming a PAI system, as well as the trends in data processing and image reconstruction algorithms. It describes in details the main features of PAI, which makes it a powerful technique for clinical applications.

Four implementations of PAI are possible, making it a tool that easily adapts to the clinical need: Handheld PAI devices (HPAT) have been developed for point-of-care applications like dermatology or oncology diagnosis at the doctor’s office.

Endoscopes integrating PAI have been demonstrated for cardiovascular imaging inside arteries. Photoacoustic computed tomography (PACT) allows 3D imaging of organs. PAI can also be implemented in a microscope (PAM) for in vitro or ex vivo diagnosis.

However, the access to the clinical market is long and complex. One of the challenges is the acceptance of PAI by clinicians. To overcome this challenge, first clinical devices expected to be adopted are systems combining ultra-sounds and PAI. Indeed, ultrasonography (US) is a well-known and well-established technique. However, it provides only structural information. PAI brings functional information to US imaging.

Moreover, the entry of PAI into clinical applications is going to be boosted by the growing number of companies – startups and large firms like Fujifilm or Canon – that are investing in this technology.

In the report, we point out the remaining challenges for clinical adoption of PAI, the issues to overcome to get a large imaging market share and a roadmap of the forthcoming clinical product.

---

**Authors**

Clémentine Bouyé is Senior Analyst and Publication Manager at Tematys. She is an expert in photonics industrial markets and technologies. She manages the production of several study reports on the market and trends of photonics technologies.

Marc Faucheux, PhD, has worked more than thirty years in the Photonics industry, first in aeronautic and spatial photonics, then as manager of medical laser development at Quantel. He has a large experience in the development of photonic devices. Based on this, he has created in 2010 the consulting activity of LMDC.